Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | PNP | P00491 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16276016 | 0.75 | HPRT1 (0.50) | LMNAALDH1A1ALBMAPK1HPRT1 | |
| SCHEMBL5438533 | 0.69 | ALDH1A1 (0.58) | LMNAALDH1A1ALBMAPK1HPRT1 | |
| SCHEMBL7389719 | 0.67 | HPRT1 (0.47) | HPRT1PNP | |
| SCHEMBL28769227 | 0.67 | ALDH1A1 (0.49) | LMNAALDH1A1ALBMAPK1HPRT1 | |
| SCHEMBL8922846 | 0.65 | ALDH1A1 (0.69) | LMNAALDH1A1ALBMAPK1HPRT1 | |
| SCHEMBL8791177 | 0.65 | HPRT1 (0.51) | LMNAALDH1A1ALBMAPK1HPRT1 | |
| SCHEMBL21362204 | 0.65 | HPRT1 (0.51) | LMNAALDH1A1ALBMAPK1HPRT1 | |
| SCHEMBL13145301 | 0.65 | HPRT1 (0.51) | LMNAALDH1A1ALBMAPK1HPRT1 | |
| SCHEMBL2679158 | 0.64 | ALDH1A1 (0.49) | LMNAALDH1A1ALBMAPK1HPRT1 | |
| Didanosine SCHEMBL16695883 | 0.64 | ALDH1A1 (1.00) | LMNAALDH1A1ALBMAPK1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | LMNA 4529/4885ALDH1A1 897/4885ALB 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.